Amidst intensifying global competition for cancer drugs, anticancer raw materials (APIs, key intermediates, ADC payloads and linkers, PROTACs/TPDs, small nucleic acid delivery materials, etc.) are entering a new cycle characterized by high quality, rapid iteration, and strong compliance. Leading R&D and CDMO companies are adjusting their strategies: on the one hand, they are increasing their investment in complex small molecule processes, antibody-conjugated payloads, and intelligent linker platforms; on the other hand, they are deepening their quality systems and promoting data-centric, full-process traceability and continuous validation, helping clients shorten the path from molecule to clinic while significantly reducing technical and compliance risks.
On the R&D front, differentiated strategies are becoming increasingly clear. Small molecules continue to iterate around kinases, DNA damage repair (DDR), and immune modulatory targets; ADC payloads are expanding from traditional microtubule inhibitors to novel mechanisms, with linker design emphasizing stability and tumor microenvironment triggering; PROTACs/TPDs focus on the selective degradation of refractory targets; and for small nucleic acids such as mRNA/siRNA, chemical modification and process scale-up and quality control of delivery materials (liposomes, polymers, peptides) are becoming key challenges. Suppliers with comprehensive cross-platform capabilities are more likely to form early joint development partnerships and long-term partnerships with pharmaceutical companies.
Process and scale-up are moving towards "compliance by design." The QbD concept incorporates early intervention from route screening, prioritizing raw material purity, isomers/potentially genotoxic impurities (PGIs), and residual solvent control. Continuous processing and flow chemistry are used to improve safety and consistency. ADC production emphasizes controllable conjugation sites and DAR distribution, with in-line/near-line PAT and statistical process control (SPC) enabling rapid closed-loop optimization. Small nucleic acid and carrier material scale-up relies heavily on sterility, endotoxin, and particle control capabilities. Mature teams are delivering "end-to-end process packages" to accelerate clients' transition from process development to GMP production.
Quality and compliance have become core criteria for clients selecting suppliers. Advanced LC-MS/MS, qNMR, ICP-MS, and multidimensional chromatography methodologies play a pivotal role in impurity profiling, metallic impurities, and residue analysis. Data integrity (ALCOA+), electronic batch records (EBR), and LIMS systems are integrated throughout R&D and commercial release. Synchronous planning of EU/US/Chinese GMP and registration documents (DMF/ASMF/CMC) facilitates international multi-center applications. In a more stringent regulatory environment, auditable, reusable, and scalable data and document assets are crucial for clients' rapid onboarding.
Flexible co-creation is becoming a trend in delivery models. From the early stages of project exploration, a multidisciplinary collaboration mechanism is established: chemistry, analytical, formulation, process engineering, and regulatory reviews are conducted concurrently, forming a phased milestone structure of "rapid prototyping - small-scale trials - pilot scale - registration batch." For potential first-line molecules, suppliers offer a combination package of "R&D vouchers + process co-creation + compliance coaching," shortening clients' preclinical timelines and ensuring transparency of progress and risks through digital project management.
For pharmaceutical and biotech companies, the new selection criteria are shifting from single-point price comparisons to end-to-end capabilities, first-batch success rates, and regulatory reliability. Partners that balance innovation and compliance, offering clients a higher probability of success and a shorter path to market, will stand out in the next round of competition.
We have built a comprehensive platform for anti-cancer raw materials, encompassing route development, scale-up validation, and GMP manufacturing for small molecules, ADC payloads and linkers, PROTAC building blocks, and small nucleic acid delivery materials. Our quality system is centered around multidimensional analysis and data integrity. If you are advancing a next-generation oncology pipeline, we welcome you to work with us to create faster, more stable, and more compliant solutions.
